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Abstract
OBJECTIVE—To estimate the effectiveness of second-trimester genetic sonography in 
modifying Down syndrome screening test results.
METHODS—The First and Second Trimester Evaluation of Risk (FASTER) aneuploidy 
screening trial participants were studied from 13 centers where a 15- to 23-week genetic sonogram 
was performed in the same center. Midtrimester Down syndrome risks were estimated for five 
screening test policies: first-trimester combined, second-trimester quadruple, and testing 
sequentially by integrated, stepwise, or contingent protocols. The maternal age-specific risk and 
the screening test risk were modified using likelihood ratios derived from the ultrasound findings. 
Separate likelihood ratios were obtained for the presence or absence of at least one major fetal 
structural malformation and for each “soft” sonographic marker statistically significant at the P<.
005 level. Detection and false-positive rate were calculated for the genetic sonogram alone and for 
each test before and after risk modification.
RESULTS—A total of 7,842 pregnancies were studied, including 59 with Down syndrome. 
Major malformations and 8 of the 18 soft markers evaluated were highly significant. The detection 
rate for a 5% false-positive rate for the genetic sonogram alone was 69%; the detection rate 
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increased from 81% to 90% with the combined test, from 81% to 90% with the quadruple test, 
from 93% to 98% with the integrated test, from 97% to 98% with the stepwise test, and from 95% 
to 97% with the contingent test. The stepwise and contingent use of the genetic sonogram after 
first-trimester screening both yielded a 90% detection rate.
CONCLUSION—Genetic sonography can increase detection rates substantially for combined and 
quadruple tests and more modestly for sequential protocols. Substituting sonography for quadruple 
markers in sequential screening was not useful.
Multiple-marker screening for Down syndrome is an established part of routine prenatal care 
in most countries. Most centers use at least three second-trimester maternal serum markers, 
many use first-trimester serum markers together with concurrent ultrasound nuchal 
translucency measurement, and some have adopted sequential policies using both first- and 
second-trimester markers.
An ultrasound anatomic survey of the fetus (genetic sonogram or anomaly scan) has also 
become widely used in the second trimester. In pregnancies at high risk of Down syndrome 
because of advanced maternal age, family history, or abnormal Down syndrome screening, 
findings from the genetic sonogram are often used to inform choice. Absence of any major 
structural abnormality or minor “soft” marker is assumed as reassuring, and invasive 
prenatal diagnosis might be avoided. Conversely, in low-risk women, the presence of these 
signs is sometimes taken as sufficient grounds for invasive testing. However, there are a 
number of inherent limitations to genetic sonograms that have limited widespread 
implementation in clinical practice.1–8 To minimize false reassurance and unnecessary 
intervention, a more formal approach to the interpretation of the sonogram is needed.
Algorithms that allow post hoc risk calculation have been published.1–4 Essentially, the risk 
obtained by Down syndrome screening is modified by likelihood ratios (LRs) derived from 
the scan. When used routinely either on all screened women or selectively, depending on the 
screening result, this could substantially increase Down syndrome detection.
The First and Second Trimester Evaluation of Risk (FASTER) trial9 is in a unique position 
to estimate the increase in detection of Down syndrome fetuses with the addition of genetic 
sonography. The trial involved prospective screening in both the first and the second 
trimesters where intervention was delayed until the second trimester. For a large proportion 
of pregnancies, intervention was further delayed until a genetic sonogram was performed, 
either at a FASTER center or elsewhere. In the current article, we evaluated the role of 
genetic sonography as an adjunct to other first- and second-trimester screening tests.
MATERIALS AND METHODS
The detailed protocol for the FASTER trial has been published elsewhere.9 Briefly, 15 
centers in the United States enrolled women who underwent a first-trimester nuchal 
translucency scan concurrently with the first-trimester maternal serum markers pregnancy-
associated plasma protein A (PAPP-A) and free β-hCG, and in the second trimester α-
fetoprotein, unconjugated estriol, free β-hCG and inhibin-A. Not all women completed the 
process; in particular, those found on nuchal translucency scan to have a septated cystic 
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hygroma were offered immediate invasive pre-natal diagnosis. Those who completed the 
planned testing were offered prenatal diagnosis if the risk based on either the first- or the 
second-trimester components of the testing was high.
The current study was restricted to women with singleton pregnancies who had screening 
tests both at 11–13 weeks and at 15–18 weeks of gestation and had a genetic sonogram at 
15–23 weeks in the same FASTER center in which they were enrolled. Women included for 
analysis in our current study had a genetic sonogram completed at 15–23 weeks, with the 
majority completing the test from 17 to 21 completed weeks of gestation. In total, among the 
33,546 trial participants with complete first- and second-trimester data, 8,533 also 
underwent genetic sonography at a FASTER center. However, because we sought to estimate 
the benefits of genetic sonography in modifying Down syndrome screening tests using all 
current methods of screening (combined, quadruple, integrated, stepwise, and contingent), 
our analysis was restricted to the 7,842 pregnancies from 13 centers out of 28,198 with 
complete screening test results at those centers (28%). There were 84 pregnancies with 
Down syndrome at those centers, and 59 of 84 (70%) underwent genetic sonography and 
had complete screening.
Six of the 13 centers performed the majority of genetic sonograms, and at those centers the 
proportions of screened participants who had a genetic sonogram were 53% (83%, 76%, 
74%, 29%, 29%, and 29% at each center). The incidence of Down syndrome at these centers 
was 4.7 in 1,000, compared with 2.6 in 1,000 (87 in 33,546) in FASTER as a whole. The 
remaining 7 centers only provided 191 genetic sonograms (1.4% of those screened), and the 
Down syndrome incidence was 120 in 1,000. These remaining 7 centers were therefore 
considered separately in the analysis because of potential surveillance bias.
Midtrimester Down syndrome risks were calculated for five standard screening tests using 
published parameters derived from the FASTER trial.10 The tests are defined as first 
trimester combined (11- to 13-week PAPP-A, free β-hCG, and nuchal translucency), second-
trimester quadruple (15- to 18-week α-fetoprotein, unconjugated estriol, free β-hCG, and 
inhibin), and the following sequential protocols: integrated (PAPP-A, nuchal translucency, 
and quadruple markers), stepwise (combined markers and, unless the risk exceeds 1 in 30, 
quadruple markers), and contingent (combined markers and, if the risk is 1 in 30–1,500, 
quadruple markers). For those having the quadruple markers in the stepwise and contingent 
tests, the risk is calculated from all seven markers.
Each center conducted the fetal anatomic survey according to the practice guideline of the 
American Institute of Ultrasound in Medicine.11 Measurements were obtained for the 
biparietal diameter, head and abdominal circumferences, and femoral and humeral lengths. 
Reduced long bones are markers of Down syndrome, and these measurements were 
expressed in multiples of the gestation-specific median (MoM) in unaffected pregnancies 
using regression. After previous practice, a femur length less than 0.91 MoM or humerus 
length less than 0.89 MoM was regarded as reduced.6 A structured report form was used to 
record at the time of the sonogram the presence or absence of the following potential soft 
markers: nuchal skin-fold 6 mm or more, choroid plexus cyst, enlarged cisterna magna over 
10 mm, ventriculomegaly 10 mm or more, echogenic intracardiac focus, pericardial effusion, 
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hydrops, echogenic bowel (with echogenicity equal to adjacent bone), liver calcification, 
pyelectasis of 3 mm or more, two-vessel umbilical cord, polydactyly, clinodactyly, sandal 
gap, and club foot. The presence of any putative major structural abnormality was recorded
—diaphragmatic hernia, spinal, cardiac, other thoracic, abdominal, and extremities—as well 
as a description of the abnormality. General observations made by the person performing the 
scan were also recorded. The descriptions of abnormalities and general observations were 
reviewed without knowledge of fetal karyotype and were classified as major or not.
In our analysis, we distinguish between nuchal translucency and nuchal fold in the following 
fashion. In accordance with the parent trial and current standard sonographic procedures, 
nuchal translucency describes the translucent nuchal space as viewed in the midsagittal 
plane during the first trimester (11 to 13 and 6/7 weeks). The nuchal fold assessment is 
distinct from the assessment of nuchal translucency because it is obtained in the 
midtrimester and taken in the axial plane, where the measurement is attained from the outer 
edge of the occipital bone to the outer margin of the skin.
The presence of at least one major abnormality and each of the 18 potential soft markers 
separately in Down syndrome and unaffected pregnancies was assessed by a χ2 test. Only 
those where there was a statistically significant (P<.005) difference were included in further 
analyses. Likelihood ratios for the presence and absence of a major abnormality or soft 
marker were computed, as well as the LR for the absence of any abnormality or marker. For 
the long bone measurements, LRs were also computed for each MoM value using log 
gaussian frequency distributions with the observed means and standard deviations in Down 
syndrome and unaffected pregnancies.
For each woman in the study, an overall LR was calculated from the product of the 
individual LR in turn corresponding to the presence and absence of an abnormality or 
marker. When none were present, the overall LR was the directly computed value. The 
Down syndrome risk based on maternal age alone and each of the screening tests, 
respectively, was modified by multiplying the odds by the overall LR. To do this, the risk 
was first expressed as an odds, which was then multiplied by the LR and reexpressed in 
terms of risk, as described by Royston and Thompson.12 In general, the LR for the presence 
of a useful marker is greater than 2, and that for absence will be somewhat less than 1 but 
not markedly so. Thus, the presence of even a single isolated marker is likely to increase the 
Down syndrome risk. However, if that marker is relatively weak, it may be considerably 
offset by the absence of other stronger markers when multiplied together.
For the genetic sonogram alone, the 92nd–99th percentiles of risk were computed, and the 
detection rate was calculated using these as the cutoff risks. This detection rate for a fixed 
5% false-positive rate was similarly calculated for the five screening tests before and after 
risk was modified by the genetic sonogram results. In addition, the detection rates were 
calculated for policies of substituting the genetic sonogram for biochemistry as the second 
stage of stepwise and contingent tests. Detection and false-positive rates were also calculated 
using a fixed 1 in 270 midtrimester risk cutoff. Pearson correlation coefficients were 
calculated, after logarithmic transformation, between each of the seven Down syndrome 
screening markers, in MoMs, and the overall LR. Pearson correlation coefficients were also 
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calculated between femur and humerus length, in MoMs, after logarithmic transformation. 
To avoid the influence of extreme outliers, results exceeding three standard deviations from 
the mean were excluded.
During the trial, patients who remained at their original FASTER site for genetic sonography 
were counseled about any soft markers based on accepted clinical practice and policies in 
place at the time of study initiation. The LRs cited herein were not available to clinicians and 
hence were not used to inform decision making or choice.
RESULTS
The mean (±SD) maternal age in the study was 30.6±6.1 years, consistent with recent U.S. 
estimates on the mean maternal age distribution approximating 28 years.13 Table 1 compares 
the patient characteristics of those who had a genetic sonogram at one of the 13 participating 
FASTER centers compared with those who were not scanned there. The cohort who received 
a genetic sonogram at a FASTER center did not differ from the index study population by 
virtue of mean maternal age (30.6±6.1 compared with 30.1±5.8 years), advanced maternal 
age, body mass index (25.1±5.2 compared with 25.1±5.3 kg/m2), or obesity (body mass 
index 30 kg/m2 or greater) (Table 1). The cohort receiving a genetic sonogram had a higher a 
priori risk of Down syndrome, but not markedly so (Table 1). A significantly greater 
proportion of women self-identifying as of Hispanic origin underwent genetic sonography 
because the FASTER center contributing the largest number of sonographic examinations 
had a 68% Hispanic population (Table 1).
Major malformations and 8 of the 18 soft markers evaluated were highly significantly 
associated with Down syndrome (Table 2). The proportions of Down syndrome and 
unaffected pregnancies with the presence of a malformation or soft marker is shown are 
Table 2, together with the LRs for presence and absence. The LR for findings in isolation are 
also represented in Table 2 and, as expected, are appreciably lower than when considered in 
combination. Table 2 also shows the LR for sonograms where none of the highly significant 
factors are present (no markers present). The value of 0.41 is higher than that obtained by 
multiplying together the LRs for absence of each factor separately (0.32), because of some 
degree of correlation between the factors.
Femur and humerus length MoM values were highly correlated in the 25 Down syndrome 
pregnancies with both measurements (r=0.57) and the 3,777 unaffected pregnancies 
(r=0.76). For this reason and because humerus length was not recorded in approximately 
half the pregnancies, only the femur length MoMs were used in the calculation of risk. The 
means and log10 standard deviations of femur length were 0.94 and 0.034 MoM in Down 
syndrome and 1.00 and 0.030 MoM in unaffected pregnancies.
The detection rates of the genetic sonogram alone, for a fixed 1–8% false-positive rate, were 
39% (23/59), 49% (29/59), 59% (35/59), 66% (39/59), 69% (41/59), 75% (44/59), 80% 
(47/59), and 83% (49/59). The detection and false-positive rates for a 1 in 270 midtrimester 
risk cutoff were 83% (49/59) and 12% (922/7,783).
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There was some evidence of biased interpretation of the genetic sonogram in the minor 
centers where the prior risk of Down syndrome was considerably increased. The overall LR 
was a little larger: a median of 0.36, compared with 0.30 in the major centers (P<.05). 
However, this did not seem to alter the results markedly. The false-positive rate was higher 
(23% compared with 12%), but this was largely due to more advanced maternal age, with 
medians of 34.8 and 31.7 years among unaffected pregnancies in the two groups, 
respectively. Moreover, the detection rate was lower (74% compared with 89%), although 
this was not statistically significant (P=.23).
Two-thirds of genetic sonograms (65%) were performed at 17–20 weeks of gestation, with 
18% at 15–16 weeks and 17% at 21–23 weeks. The detection and false-positive rates for a 1 
in 270 midtrimester risk cutoff were similar at the modal time (83% and 10%) to earlier or 
later (83% and 14%).
None of the seven Down syndrome screening markers were highly correlated with the 
overall LR from the genetic sonogram. In unaffected pregnancies, the r values ranged 
between −0.04 and 0.03; in Down syndrome pregnancies, the values were higher, ranging 
from −0.10 to 0.24, but did not reach statistical significance. Hence, any underlying 
associations are likely to be too small to invalidate the use of the overall LR to modify Down 
syndrome risk regardless of the screening marker profile.
Table 3 shows the detection rate for 5% false-positive rate for the five standard Down 
syndrome screening tests before and after the genetic sonogram. There was a 9–11% 
increase in detection for the first- and second-trimester tests, a 5% increase for the integrated 
test, and a 1–2% increase for the other sequential screening tests. The increases in detection 
after a genetic sonogram were statistically significant for the first- and second-trimester tests 
and the integrated test (P<.05, McNemar test, one-tailed). Table 3 also shows that the 
stepwise and contingent use of the genetic sonogram after first-trimester screening yielded 
the same detection rate as for routine use. However, the detection rates were lower than for 
standard stepwise and contingent tests that use the quadruple markers. Table 4 shows the 
detection and false-positive rates for all the screening options using a fixed 1 in 270 risk 
cutoff.
DISCUSSION
We have demonstrated in a large prospective study that the use of the genetic sonogram to 
modify Down syndrome risk after a second-trimester quadruple test can substantially 
increase the detection rate. Our analysis further establishes that the first-trimester combined 
test results can be substantially improved even when only women with borderline risks have 
the procedure. In contrast, the sequential screening results were only modestly improved 
with the addition of the genetic sonogram. Although Smith-Bindman et al1,7 have studied a 
large number of women who underwent genetic sonogram after being determined to be at 
high risk of aneuploidy after Down syndrome screening, our current study is the only large-
scale prospective investigation that has directly compared the effect of using the genetic 
sonogram routinely after different Down syndrome screening tests.
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A clear limitation of our study is that only 28% of FASTER pregnancies in the 13 
contributing centers had a genetic sonogram in that center; others would have had genetic 
sonograms elsewhere (non-FASTER site) or not at all. The incidence of Down syndrome in 
the overall FASTER cohort was 2.6 in 1,000. By comparison, in these centers contributing 
genetic sonography data, the Down syndrome incidence was 4.7 in 1,000. Although this 
raises the possibility of ascertainment bias in our study population, we believe that this is not 
likely to be significant for several reasons. First, we included all patients who remained at 
their FASTER site of enrollment for their antenatal care and received a genetic sonogram at 
that site. These were therefore unselected patients at each site, rather than patients 
specifically referred because of abnormal screening or sonographic abnormalities. Second, 
the genetic sonogram results in the study as a whole were largely uncorrelated with 
screening marker levels.
We have calculated risk using an overall LR obtained from the product of the individual LRs 
for the presence or absence of a serious abnormality and for each soft marker in turn. 
Another approach is to multiply the appropriate LR for abnormality by LRs corresponding 
to the number of soft markers observed. The LRs for zero, one, two, and three or more soft 
markers were 0.46, 3.1, 21, and 170. Using this method, the detection rate for a 5% false-
positive rate was 63%, which is lower than the 69% we obtained using the LR product 
method for the same false-positive rate.
Some genetic sonogram studies have also provided LRs for the presence of each soft marker 
when it is an isolated finding. We do not advocate such an approach because even in the 
largest series the LR will necessarily be based on small numbers of cases. For example, in 
our study isolated echogenic bowel was found in only one Down syndrome and 28 
unaffected pregnancies, so the observed LR of 4.7 is subject to considerable imprecision. 
The value obtained from Table 2 by multiplying LR+ for echogenic bowel and each LR− for 
the remaining markers is 10. This is a statistically more robust estimate for risk calculation.
Although the direct comparison between the five standard tests with and without the genetic 
sonogram is a simple means of assessing the gain in detection achieved by the sonogram, it 
does not provide a reliable estimate of detection rates for any of them. The rates are 
underestimated because some early detected cases, particularly those with cystic hygromas, 
were excluded. Conversely, there will be overestimation due to the viability bias inherent in 
intervention studies arising from the termination of nonviable Down syndrome pregnancies. 
Furthermore, any individual study of routine Down syndrome screening has insufficient 
statistical power to precisely estimate detection rates because of the relatively low incidence 
of the disorder. Our study included just 59 cases, and with these numbers, eg, an observed 
95% detection rate would have a 95% confidence interval of 86–99%.
Increased nuchal fold was the strongest soft marker studied. The FASTER trial was 
conducted in a period when the practice was to interpret nuchal fold dichotomously, with an 
increase defined against a fixed cutoff in millimeters. Subsequently, it has been shown that 
nuchal fold, like nuchal translucency, is best expressed in MoMs and LRs calculated 
continuously from a log gaussian distribution.14,15 Had the actual nuchal fold measurements 
Aagaard-Tillery et al. Page 7













been recorded in this study, it is likely that higher detection rates would have been 
demonstrated for policies using the genetic sonogram.
A major structural malformation was observed in 8.5% of Down syndrome pregnancies, a 
much lower rate than in other studies. This may be due to the diagnosis of such 
malformations earlier in pregnancy after the nuchal translucency scan performed in 
FASTER. For example, in the genetic sonogram study of Nyberg et al,2 the structural 
malformation rate was 17% (31/186), but half (16) had a cystic hygroma or hydrops, 
conditions likely to have been detected earlier in FASTER. Another reason for differences in 
the observed rate is the definition of a major malformation. For example, Bromley et al3 
observed a rate of 27% (44/164), but one-third (16) had ventriculomegaly, which we define 
as a marker rather than a malformation.
It is usual practice to define echogenic bowel only when the echogenicity is as bright as 
adjacent bone. However, in our study we classified this as marked echogenic bowel and also 
recorded whether there was more moderate echogenicity. There was a highly statistically 
significantly association with Down syndrome for both marked and moderate echogenic 
bowel. Also, unexpectedly, the two LRs were almost identical, rather than that for marked 
echogenic bowel being greater than for moderate. One explanation is that sonographers had 
difficulty distinguishing the extent of brightness compared with bone, which is consistent 
with the reported frequency of these markers. Among unaffected pregnancies, 0.51% were 
reported as having either marked or moderate echogenic bowel, a similar frequency to that 
for echogenic bowel in three large studies combined: 0.57% (102/17,934).1,2,7 We therefore 
combined the markers when estimating Down syndrome risk.
We found little correlation between Down syndrome screening markers and the LR from the 
genetic sonogram. Because nuchal fold was a major contributor to LR, some degree of 
correlation with nuchal translucency might be expected. However, three studies have directly 
compared nuchal translucency and nuchal fold and found that they can be considered 
independent determinants of Down syndrome risk.16–18
Two newer biometric markers of the fetal face, nasal bone length and prenasal translucency, 
not included in the study, have great potential in Down syndrome risk assessment. Statistical 
modeling indicated that they together with nuchal fold can achieve very high detection rates 
even when a full genetic sonogram is not performed.19,20 A third new facial marker, frontal 
maxillary angle,21 may improve this further.
Other authors have provided estimates of detection and false-positive rates with 
incorporation of genetic sonogram by statistical modeling using data from published studies 
to model the effectiveness of second-trimester sonography. Krantz et al22 performed 
statistical modeling to predict the effect of stepwise sequential and contingent use of the 
genetic sonogram after a combined test. There was a predicted 6% increase in detection with 
a 1.2% increased false-positive rate for the stepwise policy and 5% and 0.7%, respectively, 
for the contingent approach. We found a smaller 2% increase in detection for both policies 
but a reduction in the false-positive rate. Benn and Egan23 used modeling to predict the use 
of the genetic sonogram in combination with second-trimester triple and quadruple tests. 
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They predicted an increase in the detection rate for a 5% false-positive rate by 5% and 4% 
for the two tests, respectively. This is a much smaller gain for the quadruple test than the 
11% we observed. Finally, Weisz et al24 conducted a small prospective study of the 
integrated test followed by the genetic sonogram. There were 2,332 screened pregnancies, 
including 12 with Down syndrome. The use of LRs from the genetic sonogram reduced the 
detection rate by 8% and the false-positive rate by 0.7–1.2%, depending on the risk cutoff. 
We found an increased detection rate for this test and an even greater reduction in the false-
positive rate.
Although practitioners and patients may wish to use data derived from studies such as ours 
to provide threshold values where invasive testing may be warranted, we would caution 
against use of our data in such a manner. Decisions pertaining to further invasive testing are 
ultimately highly individualized and value laden. It is our desire that the LRs reported herein 
be used in guiding discussions among providers and patients to optimize individualized 
assessment of risk.
In conclusion, using our unique population of prospectively collected first- and second-
trimester serum and sonographic screening data, we have demonstrated that genetic 
sonography can substantially increase the Down syndrome detection rates for the first-
trimester combined and second-trimester quadruple tests. We have also shown more modest 
improvements in the detection rates for sequential tests when genetic sonography is added. 
These results support the continued use of genetic sonography in antenatal care with two 
provisos. First, the sonogram should be performed in centers with sufficient experience of 
the techniques. Second, the results of the sonogram should be used in combination with 
prior screening data to provide each patient with an individual risk assessment.
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Table 1
Patient Characteristics According to Whether a Genetic Sonogram Was Performed in the Same Center
Characteristic
Genetic Sonogram Performed in Same 
FASTER Center
Genetic Sonogram Not Performed in This 
FASTER Center
Maternal age 35 y or older 28 23
Combined test risk 1 or more in 270 9.2 6.8
Quadruple test risk 1 or more in 270 12 9.1
BMI 30 kg/m2 or greater 14 14
Smoker 3.4 4.8
Race/ethnicity
 Caucasian 48 71
 Hispanic 40 18
 Black 5.4 5.6
 Asian 5.2 4.4
 Other 0.6 1.0
FASTER, First and Second Trimester Evaluation of Risk; BMI, body mass index.
Data are %.
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Table 2
Genetic Sonogram: Statistically Significant* Associations With Down Syndrome
Finding Down Syndrome Unaffected Pregnancies LR+ LR−
Major malformation 5/59 (8.5%) 38/7,783 (0.49%) 17 0.92
Nuchal skinfold (6 mm or greater) 6/33 (18%) 24/6,473 (0.37%) 49 0.82
Femur length (less than 0.91 MoM) 16/56 (29%) 514/7,761 (6.6%) 4.6 0.73
Humerus length (less than 0.89 MoM) 3/26 (12%) 89/3,840 (2.3%) 5.0 0.90
Echogenic intracardiac focus (either ventricle) 15/53 (28%) 345/7,725 (4.5%) 6.3 0.75
Pyelectasis (3 mm or greater) 4/55 (7.3%) 103/7,777 (1.3%) 5.5 0.94
Marked echogenic bowel (bright as bone) 2/55 (3.6%) 12/7,778 (0.15%) 24† 0.96†
Moderate echogenic bowel 6/55 (11%) 28/7,777 (0.36%) 30† 0.89†
Ventriculomegaly (10 mm or greater) 3/54 (5.6%) 17/7,767 (0.22%) 25 0.95
No markers present‡ 21/59 (36%) 6,775/7,783 (87%) — 0.41




For either marked or moderate echogenic bowel, LR+ is 28 and LR− is 0.86.
‡
Excluding humerus length.
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Table 3
Detection Rate for a 5% False-Positive Rate With Standard Screening Policies and With Risk Modified by 
Genetic Sonogram Result






Stepwise sonogram† — 90
Contingent sonogram† — 90
Data are %.
*
Not interpreting the test until the sonogram is complete.
†
Replacing the second-stage quadruple markers with the sonogram.
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Table 4




Detection Rate False-Positive Rate Detection Rate False-Positive Rate
Combined 88 8.7 95† 6.2†
Quadruple 86 12 93 7.4
Integrated 93 7.1 98 5.2
Stepwise 97 7.2 98 5.6
Contingent 95 6.6 97 5.0
Stepwise sonogram‡ — — 95 6.2
Contingent sonogram‡ — — 93 5.8
Data are %.
*
Cutoff based on midtrimester risk: 1 in 270 for final results, 1 in 30 and 1 in 1,500 for the first-stage high and low cutoffs in contingent and 
stepwise policies.
†
Not interpreting the test until the sonogram is complete.
‡
Replacing the second-stage quadruple markers with the sonogram.
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